Evidence map›Paper›PMID 42232638›Full record

ArticleLivers2026

Are CD4

Antonios Katsounas, Amer Nashtar, Jasmin Weninger, Michael Steckstor, Despoina Koulenti, Joshua D Nosanchuk, Mustafa Özcürümez, Ali Canbay, Peter M Rath

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Livers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Antonios KatsounasRuhr University Bochum, Knappschaft Kliniken University Hospital Bochum, Department of Medicine, 44892 Bochum, Germany.ORCID 0000-0002-5179-0327
Amer NashtarRuhr University Bochum, Knappschaft Kliniken University Hospital Bochum, Department of Medicine, 44892 Bochum, Germany.ORCID 0009-0009-1258-6356
Jasmin WeningerRuhr University Bochum, Knappschaft Kliniken University Hospital Bochum, Department of Medicine, 44892 Bochum, Germany.ORCID 0009-0008-7116-8931
Michael SteckstorRuhr University Bochum, Knappschaft Kliniken University Hospital Bochum, Department of Medicine, 44892 Bochum, Germany.
Despoina KoulentiDepartment of Critical Care Medicine, King's College Hospital NHS Foundation Trust, London SE5 9RS, UK.
Joshua D NosanchukDepartments of Medicine (Division of Infectious Diseases) and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, NY 10461, USA.ORCID 0000-0001-9905-5754
Mustafa ÖzcürümezRuhr University Bochum, Knappschaft Kliniken University Hospital Bochum, Department of Medicine, 44892 Bochum, Germany.
Ali CanbayRuhr University Bochum, Knappschaft Kliniken University Hospital Bochum, Department of Medicine, 44892 Bochum, Germany.ORCID 0000-0001-6069-7899
Peter M RathInstitute of Medical Microbiology, University Hospital Essen, University of Duisburg-Essen, 45122 Essen, Germany.ORCID 0009-0009-8526-1739

Funding

The biology of Cryptococcus neoformans melanizationR01AI171093 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Arturo Casadevall, JOSHUA D NOSANCHUK · 2023 to 2026
$3.2M
NIAID NIH HHS R01 AI171093
6 · The paper itself

Abstract

Background: Advanced cirrhosis induces profound CD4 Objectives: To investigate the potential association between peripheral CD4 Methods: We retrospectively analyzed 455 adults hospitalized in a single institution with hepatic disorders. CD4 Results: Among 455 patients, in-hospital mortality was 103/455 (22.6%). Of the 22 immunologically at risk patients, 15/22 had cirrhosis. PJ PCR was performed in 8/22 patients (IRC-A: 2; IRC-B: 4; IRC-C: 2), with 3/8 positive (37.5%): IRC-A (1/2), IRC-B (1/4), IRC-C (1/2). Ct values ranged from 27.0 to 31.7. Two PJ-PCR-positive cirrhotic patients (IRC-A: n = 1; IRC-C: n = 1) survived without specific anti-PJ therapy; one HIV-positive patient (IRC-B) received trimethoprim-sulfamethoxazole and survived. In-hospital mortality was 5/9 (55.6%) in IRC-A, 2/7 (28.6%) in IRC-B, and 3/6 (50.0%) in IRC-C; none of the deaths were attributable to PJ pneumonia. Conclusions: Severe CD4

Indexed as

CD4+ T-cellcirrhosis-associated immunodeficiencyopportunistic infectionPneumocystis jirovecii

Identifiers

PMID42232638
PMCPMC13225858

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.